KRAS and neoplasm: Our result was similar to the finding of Kim et al. Interestingly, coexistence of PTEN mutation and KRAS mutation in the endometrial cancer cell line is very rare, suggesting that PTEN mutation and KRAS mutation may be driving mutations of tumor development.